| human | Q5 |
| P735 | given name | Eric | Q12788459 |
| Eric | Q12788459 | ||
| P106 | occupation | researcher | Q1650915 |
| Q46715896 | "Functional" and "organic": it is getting harder to tell the difference. |
| Q22242742 | A Replication of the Autism Diagnostic Observation Schedule (ADOS) Revised Algorithms |
| Q38386828 | A Single Dose, Randomized, Controlled Proof-Of-Mechanism Study of a Novel Vasopressin 1a Receptor Antagonist (RG7713) in High-Functioning Adults with Autism Spectrum Disorder |
| Q42335456 | A Single Dose, Randomized, Controlled Proof-Of-Mechanism Study of a Novel Vasopressin 1a Receptor Antagonist (RG7713) in High-Functioning Adults with Autism Spectrum Disorder |
| Q83755841 | A decade of editing CNS spectrums: back to the future |
| Q50302455 | A double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder |
| Q50344544 | A double-blind placebo-controlled trial of fluoxetine for repetitive behaviors and global severity in adult autism spectrum disorders |
| Q79459276 | A double-blind study of citalopram versus placebo in the treatment of compulsive sexual behaviors in gay and bisexual men |
| Q44488825 | A double-blind, placebo-controlled study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive-compulsive disorder. |
| Q44312617 | A double-blind, placebo-controlled trial of clonazepam in obsessive-compulsive disorder |
| Q44835101 | A double-blind, placebo-controlled trial of topiramate for pathological gambling |
| Q45189223 | A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism |
| Q48337814 | A preliminary study of cortisol and norepinephrine reactivity to psychosocial stress in borderline personality disorder with high and low dissociation |
| Q34369561 | A qualitative analysis of nonresponse: management of treatment-refractory obsessive-compulsive disorder. |
| Q35185867 | A review of pharmacologic treatments for obsessive-compulsive disorder |
| Q44662798 | Acute and long-term treatment and prevention of relapse of obsessive-compulsive disorder with paroxetine |
| Q51876822 | Addressing underserved populations and unmet needs. |
| Q45418936 | Adequacy of pharmacotherapy among medicaid-enrolled patients newly diagnosed with obsessive-compulsive disorder |
| Q39302260 | An expert opinion on PANDAS/PANS: highlights and controversies |
| Q51751264 | An open-label trial of divalproex extended-release in the treatment of borderline personality disorder. |
| Q46786002 | An open-label trial of venlafaxine in body dysmorphic disorder. |
| Q60628996 | Antiepileptic Drugs in the Treatment of Impulsivity and Aggression and Impulse Control and Cluster B Personality Disorders |
| Q34374130 | Antiepileptic medications in autism spectrum disorder: a systematic review and meta-analysis |
| Q38220018 | Anxiety and OC spectrum disorders over life cycle |
| Q42327831 | Are there new advances in the pharmacotherapy of autism spectrum disorders? |
| Q48369627 | Association analysis of the NrCAM gene in autism and in subsets of families with severe obsessive-compulsive or self-stimulatory behaviors |
| Q37374276 | Autism and oxytocin: new developments in translational approaches to therapeutics |
| Q46982678 | Autism-related routines and rituals associated with a mitochondrial aspartate/glutamate carrier SLC25A12 polymorphism |
| Q43001389 | Basal Ganglia activity in pathological gambling: a fluorodeoxyglucose-positron emission tomography study |
| Q37019876 | Baseline factors predicting placebo response to treatment in children and adolescents with autism spectrum disorders: a multisite randomized clinical trial |
| Q52294306 | Behavioral addictions and dirty drugs. |
| Q38965486 | Behavioral phenotype in a child with Prader-Willi syndrome and comorbid 47, XYY. |
| Q38722310 | Better than treated as usual: Transcranial magnetic stimulation augmentation in selective serotonin reuptake inhibitor-refractory obsessive-compulsive disorder, mini-review and pilot open-label trial |
| Q40466730 | Beyond refractory obsessions and anxiety states: toward remission. |
| Q46024579 | Bipolar disorder and comorbid attention deficit hyperactivity disorder. A distinct clinical phenotype? Clinical characteristics and temperamental traits. |
| Q50345374 | Body Dysmorphic Disorder in Patients With Autism Spectrum Disorder: A Reflection of Increased Local Processing and Self-Focus |
| Q102368966 | Body dysmorphic disorder: a treatment synthesis and consensus on behalf of the International College of Obsessive-Compulsive Spectrum Disorders and the Obsessive Compulsive and Related Disorders Network of the European College of Neuropsychopharmaco |
| Q36339814 | Brain stimulation techniques in the treatment of obsessive-compulsive disorder: current and future directions |
| Q81072398 | Brain stimulation, alternative medicine, and impulsivity and compulsivity |
| Q34665596 | Brief report: parental age and the sex ratio in autism |
| Q35813203 | Catalysts for Change: The Role of Small Business Funders in the Creation and Dissemination of Innovation |
| Q45157263 | Characterizing impulsivity profile in patients with obsessive-compulsive disorder |
| Q38969418 | Childhood, adolescent and adult age at onset and related clinical correlates in obsessive-compulsive disorder: a report from the International College of Obsessive-Compulsive Spectrum Disorders (ICOCS). |
| Q48949890 | Cigarette smoking in patients with obsessive compulsive disorder: a report from the International College of Obsessive Compulsive Spectrum Disorders (ICOCS). |
| Q95315778 | Clinical advances in obsessive-compulsive disorder: a position statement by the International College of Obsessive-Compulsive Spectrum Disorders |
| Q56910732 | Clinical and research issues in depersonalization syndrome |
| Q100392211 | Clinical characteristics and comorbidity associated with female gender in obsessive-compulsive disorder |
| Q37117775 | Clinical evidence and potential neurobiological underpinnings of unresolved symptoms of depression |
| Q88679842 | Clinical features associated with increased severity of illness in tertiary clinic referred patients with obsessive compulsive disorder |
| Q44785566 | Comorbidity in compulsive hoarding: a case report. |
| Q46222095 | Comorbidity in obsessive-compulsive disorder (OCD): a report from the International College of Obsessive-Compulsive Spectrum Disorders (ICOCS). |
| Q24810652 | Comorbidity issues in the pharmacological treatment of Pathological Gambling: a critical review. |
| Q80359164 | Comprehensive treatment of three patients with comorbid OCPD and ADHD |
| Q48840579 | Compulsivity and impulsivity-personal reflections: why now and why here? |
| Q64230853 | Compulsivity in Alcohol Use Disorder and Obsessive Compulsive Disorder: Implications for Neuromodulation |
| Q38162524 | Compulsivity, impulsivity, and the DSM-5 process |
| Q94523108 | Correction to: Exploring Social Biomarkers in High‑Functioning Adults with Autism and Asperger's Versus Healthy Controls: A Cross‑Sectional Analysis |
| Q45280768 | Cross-cutting issues and future directions for the OCD spectrum |
| Q50310405 | Design and subject characteristics in the federally-funded citalopram trial in children with pervasive developmental disorders |
| Q35173334 | Development and validation of the appearance and performance enhancing drug use schedule |
| Q34577179 | Diagnosis and treatment of body dysmorphic disorder in adolescents |
| Q35103438 | Diagnosis and treatment of pathologic gambling |
| Q39157242 | Diametrical relationship between gray and white matter volumes in autism spectrum disorder and schizophrenia |
| Q40785728 | Differential Effects of Oxytocin on Agency and Communion for Anxiously and Avoidantly Attached Individuals |
| Q46528701 | Differential treatment response, neuroinflammation, and psychosis associated with chromosome deletion |
| Q60628991 | Disruptive, Impulse Control, and Conduct Disorders: Intermittent Explosive Disorder, Kleptomania, and Pyromania |
| Q42026723 | Dissociation and posttraumatic stress 1 year after the World Trade Center disaster: follow-up of a longitudinal survey. |
| Q44407169 | Divalproex in the Treatment of Impulsive Aggression: Efficacy in Cluster B Personality Disorders |
| Q33757565 | Divalproex sodium vs placebo for the treatment of irritability in children and adolescents with autism spectrum disorders |
| Q46826680 | Divalproex sodium vs. placebo in the treatment of repetitive behaviours in autism spectrum disorder |
| Q50303347 | Divalproex versus placebo for the prevention of irritability associated with fluoxetine treatment in autism spectrum disorder |
| Q34380515 | Does sustained-release lithium reduce impulsive gambling and affective instability versus placebo in pathological gamblers with bipolar spectrum disorders? |
| Q38500360 | Double-Blind, Placebo-Controlled Trial of Topiramate Augmentation in Treatment-Resistant Obsessive-Compulsive Disorder |
| Q60180538 | EXPLORING SOCIODEMOGRAPHIC AND CLINICAL CORRELATES OF OLDER ADULTS WITH OBSESSIVE-COMPULSIVE DISORDER: A REPORT FROM THE INTERNATIONAL COLLEGE OF OBSESSIVE-COMPULSIVE DISORDERS (ICOCS) |
| Q63684018 | Early intervention for obsessive compulsive disorder: An expert consensus statement |
| Q40648193 | Effects of age and symptomatology on cortical thickness in autism spectrum disorders |
| Q92165453 | Efficacy and Safety of Deep Transcranial Magnetic Stimulation for Obsessive-Compulsive Disorder: A Prospective Multicenter Randomized Double-Blind Placebo-Controlled Trial |
| Q26285020 | Efficacy and safety of deep transcranial magnetic stimulation for major depression: a prospective multicenter randomized controlled trial |
| Q46817615 | Enhanced cortisol suppression in eating disorders with impulsive personality features |
| Q24669677 | Epidemiologic and clinical updates on impulse control disorders: a critical review |
| Q38391894 | Escitalopram in the treatment of impulsive-compulsive internet usage disorder: an open-label trial followed by a double-blind discontinuation phase. |
| Q44560011 | Evidence that eicosapentaenoic acid is effective in treating autism. |
| Q38607739 | Excitatory/inhibitory imbalance in autism spectrum disorders: Implications for interventions and therapeutics |
| Q37244055 | Experimental therapeutics for refractory obsessive-compulsive disorder: translational approaches and new somatic developments |
| Q91832063 | Exploring Social Biomarkers in High-Functioning Adults with Autism and Asperger's Versus Healthy Controls: A Cross-Sectional Analysis |
| Q33684282 | Exploring the manifestations of anxiety in children with autism spectrum disorders |
| Q43005088 | Extended-release fluvoxamine and improvements in quality of life in patients with obsessive-compulsive disorder |
| Q46379152 | FDG-PET study in pathological gamblers. 1. Lithium increases orbitofrontal, dorsolateral and cingulate metabolism |
| Q50346382 | Factor analysis of repetitive behaviors in Autism as measured by the Y-BOCS. |
| Q50341441 | Familial associations of intense preoccupations, an empirical factor of the restricted, repetitive behaviors and interests domain of autism |
| Q50302866 | Family-based association study of TPH1 and TPH2 polymorphisms in autism |
| Q36326268 | Fluvoxamine: a selective serotonin re-uptake inhibitor for the treatment of obsessive-compulsive disorder |
| Q57161745 | From Treatment Response to Recovery - a Realistic Goal in OCD |
| Q48935413 | Fronto-thalamo-striatal gray and white matter volumes and anisotropy of their connections in bipolar spectrum illnesses |
| Q36373535 | Functional deficits of the attentional networks in autism |
| Q34271431 | Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care |
| Q50875409 | Happy New 2008: from mild cognitive impairment to pleasure circuitry. |
| Q46697887 | Imaging monetary reward in pathological gamblers |
| Q39748745 | Impact of a switch to fingolimod on depressive symptoms in patients with relapsing multiple sclerosis: An analysis from the EPOC (Evaluate Patient OutComes) trial |
| Q35681700 | Impact of recent findings on study design of future autism clinical trials |
| Q45292059 | Impact of trait impulsivity and state aggression on divalproex versus placebo response in borderline personality disorder |
| Q28742335 | Impaired structural connectivity of socio-emotional circuits in autism spectrum disorders: a diffusion tensor imaging study |
| Q37106332 | Impulsive-compulsive buying disorder: clinical overview |
| Q36673868 | Impulsive-compulsive sexual behavior |
| Q57461384 | In Search of Biomarkers for Autism Spectrum Disorder |
| Q34777549 | In vivo 1H-magnetic resonance spectroscopy study of the attentional networks in autism |
| Q44887871 | Increased repetitive behaviours and prolactin responsivity to oral m-chlorophenylpiperazine in adults with autism spectrum disorders |
| Q46836931 | Increased white matter metabolic rates in autism spectrum disorder and schizophrenia. |
| Q102062859 | Intranasal oxytocin versus placebo for hyperphagia and repetitive behaviors in children with Prader-Willi Syndrome: A randomized controlled pilot trial |
| Q36517358 | Intranasal oxytocin versus placebo in the treatment of adults with autism spectrum disorders: a randomized controlled trial |
| Q79166996 | Is compulsive buying a real disorder, and is it really compulsive? |
| Q36385259 | Is obsessive-compulsive disorder an anxiety disorder? |
| Q28247116 | Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autism |
| Q50304105 | Lack of evidence for association of the serotonin transporter gene SLC6A4 with autism |
| Q50302704 | Levetiracetam versus placebo in childhood and adolescent autism: a double-blind placebo-controlled study |
| Q92312433 | Lifetime bipolar disorder comorbidity and related clinical characteristics in patients with primary obsessive compulsive disorder: a report from the International College of Obsessive-Compulsive Spectrum Disorders (ICOCS) |
| Q44080281 | Lithium and valproate treatment of pathological gambling: a randomized single-blind study. |
| Q34019896 | Management of obsessive-compulsive disorder |
| Q27315912 | Mapping autism risk loci using genetic linkage and chromosomal rearrangements |
| Q38558284 | Mesenchymal stem cells in autism spectrum and neurodevelopmental disorders: pitfalls and potential promises |
| Q44351769 | Multicenter investigation of the opioid antagonist nalmefene in the treatment of pathological gambling |
| Q30484771 | Multiplex ligation-dependent probe amplification for genetic screening in autism spectrum disorders: efficient identification of known microduplications and identification of a novel microduplication in ASMT. |
| Q44662095 | Muscarinic targets for cognition in Schizophrenia; ADHD comorbidity; perinatal risks, treatment resistance and SRIs; and brain lesions presenting as psychiatric illness |
| Q21261438 | Mutation analysis of the NSD1 gene in patients with autism spectrum disorders and macrocephaly |
| Q36053966 | Mutation screening of the PTEN gene in patients with autism spectrum disorders and macrocephaly |
| Q34024174 | Nalmefene in the treatment of pathological gambling: multicentre, double-blind, placebo-controlled study. |
| Q44224606 | Nefazodone treatment of pathological gambling: a prospective open-label controlled trial. |
| Q98658394 | Neurocovid-19: A clinical neuroscience-based approach to reduce SARS-CoV-2 related mental health sequelae |
| Q38882554 | Neurodevelopmental Disorders (ASD and ADHD): DSM-5, ICD-10, and ICD-11. |
| Q37611274 | Neurological considerations: autism and Parkinson's disease |
| Q46875340 | Neurological soft signs as predictors of treatment response to selective serotonin reuptake inhibitors in obsessive-compulsive disorder |
| Q48512235 | New developments in autism spectrum disorders. Interview by Dr. George Lundberg. |
| Q82269885 | New insights into bipolar disorder |
| Q52595087 | New perspectives in the treatment of body dysmorphic disorder. |
| Q83237744 | New technologies: the good, the bad, and the ugly |
| Q38654018 | New treatment models for compulsive disorders |
| Q57775880 | Non-Paraphilic Compulsive Sexual Behavior and Psychiatric Co-morbidities in Gay and Bisexual Men |
| Q51902267 | OCSDs in the forthcoming DSM-V. |
| Q41809790 | Obsessive compulsive disorder comorbidity in DBA. |
| Q50345816 | Obsessive-compulsive behaviors in parents of multiplex autism families |
| Q38220363 | Obsessive-compulsive disorder and spectrum across the life span |
| Q33375375 | Obsessive-compulsive disorder spectrum as a scientific "metaphor". |
| Q28275558 | Obsessive-compulsive disorder: a review of the diagnostic criteria and possible subtypes and dimensional specifiers for DSM-V |
| Q37589172 | Obsessive-compulsive disorder: diagnostic and treatment issues |
| Q82237496 | Obsessive-compulsive spectrum disorders |
| Q51894542 | Obsessive-compulsive spectrum phenomena and the DSM-V developmental process. |
| Q44327359 | Ondansetron augmentation in patients with obsessive-compulsive disorder who are inadequate responders to serotonin reuptake inhibitors: improvement with treatment and worsening following discontinuation |
| Q34614439 | Ondansetron augmentation in treatment-resistant obsessive-compulsive disorder: a preliminary, single-blind, prospective study |
| Q46029493 | Optimal dosing of desvenlafaxine, new insights in gambling and anorexia, and caffeine-induced psychosis. |
| Q47675924 | Oxytocin and Prader-Willi Syndrome |
| Q28288567 | Oxytocin and experimental therapeutics in autism spectrum disorders |
| Q35303528 | Oxytocin can hinder trust and cooperation in borderline personality disorder |
| Q34569909 | Oxytocin increases retention of social cognition in autism |
| Q34530012 | Oxytocin infusion reduces repetitive behaviors in adults with autistic and Asperger's disorders |
| Q50666953 | Oxytocin selectively improves empathic accuracy. |
| Q67208936 | Parkinson's disease, Tourette syndrome, and the changing nature of depression: the dog days of summer. |
| Q39138789 | Pathological gambling treated with lithium: the role of assessing temperament |
| Q37954625 | Patients with obsessive-compulsive disorder vs depression have comparable health care costs: a retrospective claims analysis of Florida Medicaid enrollees |
| Q42034452 | Peritraumatic reactions associated with the World Trade Center disaster |
| Q52559579 | Pharmacological Treatment Of Body Dysmorphic Disorder. |
| Q50665402 | Pharmacological treatment strategies in obsessive compulsive disorder: A cross-sectional view in nine international OCD centers. |
| Q36079333 | Pharmacological treatments of pathological gambling |
| Q38157123 | Pharmacological, experimental therapeutic, and transcranial magnetic stimulation treatments for compulsivity and impulsivity |
| Q91635676 | Pharmacotherapy in body dysmorphic disorder: relapse prevention and novel treatments |
| Q45997321 | Positron emission tomography assessment of cerebral glucose metabolic rates in autism spectrum disorder and schizophrenia. |
| Q48534825 | Positron emission tomography imaging of risperidone augmentation in serotonin reuptake inhibitor-refractory patients |
| Q28248275 | Practice guideline for the treatment of patients with obsessive-compulsive disorder |
| Q57279152 | Preclinical Animal Models of Autistic Spectrum Disorders (ASD) |
| Q36931279 | Predicting response to opiate antagonists and placebo in the treatment of pathological gambling |
| Q101342450 | Predictors of Caregiver Strain for Parents of Children with Autism Spectrum Disorder |
| Q88338867 | Prevalence of Selective Serotonin Reuptake Inhibitor-Related Apathy in Patients With Obsessive Compulsive Disorder |
| Q38904035 | Prevalence of suicide attempt and clinical characteristics of suicide attempters with obsessive-compulsive disorder: a report from the International College of Obsessive-Compulsive Spectrum Disorders (ICOCS). |
| Q24602117 | Probing compulsive and impulsive behaviors, from animal models to endophenotypes: a narrative review |
| Q46385578 | Psychopharmacologic interventions for repetitive behaviors in autism spectrum disorders |
| Q28277860 | Psychopharmacology of aggression in children and adolescents with autism: a critical review of efficacy and tolerability |
| Q38373331 | Quality of life outcomes in patients with obsessive-compulsive disorder: relationship to treatment response and symptom relapse |
| Q91536399 | Randomized crossover feasibility trial of helminthic Trichuris suis ova versus placebo for repetitive behaviors in adult autism spectrum disorder |
| Q49090521 | Rare metabolic syndromes, a vascular hypotheses of Alzheimer's disease, and drug developments for attention and trauma. |
| Q34653925 | Refractory obsessive-compulsive disorder: state-of-the-art treatment |
| Q38423128 | Regional glucose metabolism within cortical Brodmann areas in healthy individuals and autistic patients |
| Q48042803 | Relapse Prevention and the Need for Ongoing Pharmacological Treatment in Body Dysmorphic Disorder |
| Q33625691 | Relationship between whole blood serotonin and repetitive behaviors in autism |
| Q51944284 | Relationship of personality to dissociation and childhood trauma in borderline personality disorder. |
| Q46823586 | Reliability and validity of the pathological gambling adaptation of the Yale-Brown Obsessive-Compulsive Scale (PG-YBOCS). |
| Q35067270 | Review: in obsessive-compulsive disorder, clomipramine may be more effective than selective serotonin reuptake inhibitors after controlling for other factors |
| Q44646522 | Risperidone augmentation in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study |
| Q36464516 | Selective serotonin reuptake inhibitors in autism: a review of efficacy and tolerability. |
| Q30054243 | Serotonergic Function in Obsessive-Compulsive Disorder |
| Q48422105 | Serotonin dysfunction in pathological gamblers: increased prolactin response to oral m-CPP versus placebo |
| Q43262227 | Serotonin function in pathological gambling: blunted growth hormone response to sumatriptan |
| Q35956669 | Serotonin-1D hypothesis of obsessive-compulsive disorder: an update. |
| Q36466467 | Serotonin-norepinephrine reuptake inhibitors in the treatment of obsessive-compulsive disorder: A critical review. |
| Q37138381 | Should OCD leave the anxiety disorders in DSM-V? The case for obsessive compulsive-related disorders |
| Q37700925 | Should an obsessive-compulsive spectrum grouping of disorders be included in DSM-V? |
| Q47288464 | Social anxiety in outpatients with schizophrenia: a relevant cause of disability |
| Q45711760 | Social synchrony and oxytocin: from behavior to genes to therapeutics |
| Q37107260 | Standards of care for obsessive-compulsive disorder centres |
| Q48866759 | Striatal volume on magnetic resonance imaging and repetitive behaviors in autism |
| Q44211360 | Symptom domains in autism and related conditions: evidence for familiality |
| Q35212468 | Targeted treatments for symptom domains in child and adolescent autism |
| Q35577128 | The 5-HT(2A) receptor and serotonin transporter in Asperger's disorder: A PET study with [¹¹C]MDL 100907 and [¹¹C]DASB. |
| Q57775977 | The Consequences of Compulsive Sexual Behavior: The Preliminary Reliability and Validity of the Compulsive Sexual Behavior Consequences Scale |
| Q36810215 | The Gambling Symptom Assessment Scale (G-SAS): a reliability and validity study |
| Q38846893 | The cost and impact of compulsivity: A research perspective |
| Q46616492 | The impact of comorbidity on the management of pathological gambling. |
| Q48459170 | The influence of age at onset and duration of illness on long-term outcome in patients with obsessive-compulsive disorder: a report from the International College of Obsessive Compulsive Spectrum Disorders (ICOCS). |
| Q36555044 | The neuroscience of affiliation: forging links between basic and clinical research on neuropeptides and social behavior |
| Q37559828 | The role of ionotropic glutamate receptors in childhood neurodevelopmental disorders: autism spectrum disorders and fragile x syndrome. |
| Q51894532 | The ventral striatum, hypersociability, and sleepwalking at year's end. |
| Q34565546 | Topiramate plus paroxetine in treatment-resistant obsessive-compulsive disorder |
| Q48434380 | Trauma, multiple sclerosis, delayed sleep phase disorder, subjective experiences, and duration of illness in GAD. |
| Q37104298 | Treating body dysmorphic disorder with medication: evidence, misconceptions, and a suggested approach |
| Q34756463 | Treatment non-response in OCD: methodological issues and operational definitions |
| Q46140466 | Treatment response and redefining diagnostic boundaries |
| Q44446764 | Venlafaxine in treatment-resistant obsessive-compulsive disorder. |
| Q48480894 | Volumetric analysis and three-dimensional glucose metabolic mapping of the striatum and thalamus in patients with autism spectrum disorders |
| Q63090410 | WCA Recommendations for the Long-Term Treatment of Generalized Anxiety Disorder |
| Q35651404 | WCA Recommendations for the long-term treatment of posttraumatic stress disorder. |
| Q28242781 | WCA recommendations for the long-term treatment of generalized anxiety disorder |
| Q35651392 | WCA recommendations for the long-term treatment of obsessive-compulsive disorder in adults. |
| Q35651398 | WCA recommendations for the long-term treatment of panic disorder. |
| Q35651410 | WCA recommendations for the long-term treatment of social phobia. |
| Q22305681 | World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Posttraumatic Stress Disorders |
| Q34865036 | World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision |
| Q45292352 | rTMS in resistant mixed states: an exploratory study. |
Search more.